Product
Vigabatrin
Name
Vigabatrin
INN Name
Vigabatrin
FDA Approved
Yes
4 clinical trials
18 organizations
8 indications
7 documents
Indication
SpasmIndication
Cerebral PalsyIndication
Infantile SpasmIndication
Status EpilepticusIndication
ElectrographicIndication
ComaIndication
NAFLDIndication
ObesityClinical trial
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile SpasmsStatus: Withdrawn, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile SpasmsStatus: Terminated, Estimated PCD: 2019-05-29
Clinical trial
VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIaStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
The Effect of Vigabatrin on Insulin SensitivityStatus: Recruiting, Estimated PCD: 2023-06-01
Document
DailyMed Label: VigabatrinOrganization
Actavis Pharma, Inc.Organization
Hikma Pharmaceuticals USA Inc.Organization
Cipla USA, Inc.Organization
Lupin Pharmaceuticals, Inc.Organization
Biocon Pharma Inc.Organization
Dr. Reddys Laboratories Inc.,Document
DailyMed Label: VIGADRONEOrganization
Upsher-Smith Laboratories, LLCOrganization
Novadoz Pharmaceuticals LLCDocument
DailyMed Label: VIGPODEROrganization
Pyros Pharmaceuticals, Inc.Organization
Amneal Pharmaceuticals NY LLCOrganization
Edenbridge Pharmaceuticals LLC.Document
DailyMed Label: VIGAFYDEOrganization
Aurobindo Pharma LimitedOrganization
ENDO USA, Inc.Organization
Ascend Laboratories, LLCOrganization
Camber Pharmaceuticals, Inc.Document
DailyMed Label: SABRILOrganization
Lundbeck Pharmaceuticals LLCOrganization
Zydus Pharmaceuticals (USA) Inc. Organization
Zydus Lifesciences Limited